Skip to Content
Print Share

Iclusig Dosage

Generic name: ponatinib hydrochloride 15mg
Dosage form: tablet, film coated

Medically reviewed on September 12, 2018.

Recommended Dosage

The optimal dose of Iclusig has not been identified. In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, in the Phase 2 trial, 68% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy.

Start dosing with 45 mg once daily. Consider reducing the dose of Iclusig for patients with chronic phase (CP) CML and accelerated phase (AP) CML who have achieved a major cytogenetic response.

Consider discontinuing Iclusig if response has not occurred by 3 months (90 days).

Iclusig may be taken with or without food. Tablets should be swallowed whole.

Dose Modifications for Myelosuppression

Suggested dose modifications for neutropenia (ANC* less than 1.0 × 109/L) and thrombocytopenia (platelet less than 50 × 109/L) that are unrelated to leukemia are summarized in Table 1.

Table 1: Suggested Dose Modifications for Myelosuppression
*
ANC = absolute neutrophil count
ANC* <1 × 109/L
or
platelet <50 × 109/L		 First occurrence:
  • Interrupt Iclusig and resume initial 45 mg dose after recovery to ANC ≥1.5 × 109/L and platelet ≥75 × 109/L
Second occurrence:
  • Interrupt Iclusig and resume at 30 mg after recovery to ANC ≥1.5 × 109/L and platelet ≥75 × 109/L
Third occurrence:
  • Interrupt Iclusig and resume at 15 mg after recovery to ANC ≥1.5 × 109/L and platelet ≥75 × 109/L

Dose Modifications for Non-hematologic Adverse Reactions

If a serious non-hematologic adverse reaction occurs, modify the dose, interrupt treatment, or consider discontinuation. Do not restart Iclusig in patients with arterial or venous occlusive reactions unless the potential benefit outweighs the risk of recurrent arterial or venous occlusions and the patient has no other treatment options. For serious reactions other than arterial or venous occlusion, do not restart Iclusig until the serious event has resolved or the potential benefit of resuming therapy is judged to outweigh the risk.

Hepatotoxicity

Recommended modifications for hepatotoxicity are summarized in Table 2.

Table 2: Recommended Dose Modifications for Hepatotoxicity
*
ULN = Upper Limit of Normal for the lab
Elevation of liver transaminase >3× ULN* (Grade 2 or higher) Occurrence at 45 mg:
  • Interrupt Iclusig and monitor hepatic function
  • Resume Iclusig at 30 mg after recovery to ≤ Grade 1 (<3× ULN)
Occurrence at 30 mg:
  • Interrupt Iclusig and resume at 15 mg after recovery to ≤ Grade 1
Occurrence at 15 mg:
  • Discontinue Iclusig
Elevation of AST or ALT ≥3× ULN concurrent with an elevation of bilirubin >2× ULN and alkaline phosphatase <2× ULN Discontinue Iclusig

Pancreatitis and Elevation of Lipase

Recommended modifications for pancreatic adverse reactions are summarized in Table 3.

Table 3: Recommended Dose Modifications for Pancreatitis and Elevation of Lipase
*
ULN = Upper Limit of Normal for the lab
Asymptomatic Grade 1 or 2 elevation of serum lipase Consider interruption or dose reduction of Iclusig
Asymptomatic Grade 3 or 4 elevation of lipase (>2× ULN*) or asymptomatic radiologic pancreatitis (Grade 2 pancreatitis) Occurrence at 45 mg:
  • Interrupt Iclusig and resume at 30 mg after recovery to ≤ Grade 1 (<1.5× ULN)
Occurrence at 30 mg:
  • Interrupt Iclusig and resume at 15 mg after recovery to ≤ Grade 1
Occurrence at 15 mg:
  • Discontinue Iclusig
Symptomatic Grade 3 pancreatitis Occurrence at 45 mg:
  • Interrupt Iclusig and resume at 30 mg after complete resolution of symptoms and after recovery of lipase elevation to ≤ Grade 1
Occurrence at 30 mg:
  • Interrupt Iclusig and resume at 15 mg after complete resolution of symptoms and after recovery of lipase elevation to ≤ Grade 1
Occurrence at 15 mg:
  • Discontinue Iclusig
Grade 4 pancreatitis Discontinue Iclusig

Dose Modification for Use with Strong CYP3A Inhibitors

The recommended dose should be reduced to 30 mg once daily when administering Iclusig with strong CYP3A inhibitors [see Drug Interactions (7.1)].

Dose Modification for Use in Patients with Hepatic Impairment

The recommended starting dose is 30 mg once daily in patients with hepatic impairment (Child-Pugh A, B, or C) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Next → Professional
Add to My Med List

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide